Advancing Wilson Disease Care: Evolving Approaches for Copper Control - Episode 8
Therapeutic Strategies in Wilson Disease
Learn how chelators and zinc manage copper in Wilson disease, why trientine is favored, and when maintenance therapy becomes lifelong.
In this episode, 'Therapeutic Strategies in Wilson Disease,' the panelists explore the clinical decision-making process for managing copper toxicity. Dr. Rima Fawaz provides a foundational overview of current therapies, distinguishing between chelating agents—which bind to free, non-ceruloplasmin copper and promote renal excretion—and zinc therapy, which blocks intestinal copper absorption by inducing metallothionein. The experts also note recent findings suggesting that trientine may share some of zinc's absorption-blocking properties, adding a layer of mechanistic complexity to treatment selection.
A significant portion of the discussion focuses on the "low and slow" approach to starting chelation, particularly in patients with neurological symptoms. Dr. Peter Hedera explains the risk of paradoxical worsening, a phenomenon where the mobilization of copper can cause potentially irreversible neurological deterioration. Due to a lower perceived risk of this complication and a more favorable side-effect profile, trientine is often preferred over penicillamine for initial therapy. Conversely, zinc is identified as an ideal first-line option for asymptomatic patients or those diagnosed early through sibling screening, though its slow onset of action makes it unsuitable for acute de-coppering.
The panel emphasizes that Wilson disease requires lifelong maintenance, regardless of the initial therapy used. Whether staying on a reduced dose of a chelator or transitioning to zinc, the goal remains a stable, negative copper balance. Dr. Fawaz and Dr. Hedera conclude by highlighting the practical challenges of these regimens, such as the need to separate medications from food and each other, and the ongoing importance of monitoring 24-hour urine copper levels to guide long-term clinical success.
The next episode in this series, 'Evaluating Trientine Tetrahydrochloride in Wilson Disease from the CHELATE Trial,' features the panelists advancing their conversation on Wilson disease and focusing on the clinical advantages of newer chelation formulations. The experts discuss the transition from trientine dihydrochloride to the FDA-approved tetrahydrochloride salt, emphasizing improvements in storage, dosing frequency, and patient adherence.
